The state of Colorado currently has 18 active clinical trials seeking participants for COVID19 research studies. These trials are conducted in various cities, including Denver, Aurora, Colorado Springs and Englewood.
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
Recruiting
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Gender:
All
Ages:
All
Trial Updated:
07/19/2023
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol
Recruiting
A pilot study to investigate the effects of the prone positioning (PP) on hospital patients diagnosed with COVID-19 pneumonia. Investigators that early self-proning may prevent intubation and improve mortality in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2). Up to 100 participants with a primary diagnosis of confirmed COVID-19 pneumonia will be enrolled to the study. All participants will be screened and those that meet inclusion and exclusion criteria will be en... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2022
Locations: UCHealth Poudre Valley Hospital, Fort Collins, Colorado +2 locations
Conditions: COVID-19
COVID-19 Diagnostic Self-testing Using Virtual Point-of-care
Recruiting
The goal of the research is to assess candidate COVID-19 rapid diagnostic tests (e.g. immunodiagnostic antibody tests, like Cellex qSARS-CoV-2 IgG/IgM Rapid Test, or antigen tests, like Turklab Test-It COVID-19 Home Test, AllBio Science Inc. and Artron Laboratories Inc. rapid COVID-19 antigen tests in order to judge their clinical accuracy compared to Centers for Disease Control (CDC)-recommended molecular genetic testing and clinical diagnosis. Second, it is our goal to determine if self-testin... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
03/08/2022
Locations: Neuroganics, Northglenn, Colorado
Conditions: Communicable Disease, COVID-19, Sars-CoV2, Infectious Disease, Coronavirus, Virus
National Vaccine Adverse Event Reporting Survey and Etiology
Recruiting
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms. The primary goal of this study is to create a national database and gather vaccine-associated serious adverse events/injury data from newly vaccinated individuals in the US in order to identify the possible underlying causal relationships and plausible underlying biological mechanisms. The projec... Read More
Gender:
All
Ages:
Between 5 years and 99 years
Trial Updated:
03/03/2022
Locations: Neuroganics LLC, Northglenn, Colorado
Conditions: COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
ASYMPTOMATIC AND PRE-SYMPTOMATIC TRANSMISSION OF SARS-COV-2 IN A COMMUNITY CONGREGANT SETTING
Recruiting
The overall aim of this study is to measure how transmission of COVID-19 occurs in communities - including the role of super spreaders and/or identifying conditions that may increase transmission risk, with a focus on congregant situations. In order to identify how presence of symptoms and behavior affects the transmissibility of the virus, we will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using polyvinyl alcohol (PVA) test strips embedded in face masks (Face M... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2021
Locations: Anschutz Medical Campus, Aurora, Colorado +5 locations
Conditions: COVID-19, SARS-CoV2 Infection
Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
Recruiting
Randomized, Double Blind, Placebo Controlled, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/08/2021
Locations: IMMUNOe Research Centers, Centennial, Colorado
Conditions: Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), Covid19